US › Healthcare

Immuneering Corp (IMRX)

US · Healthcare · Biotechnology

$4.40+5.52%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-13.5M

Profit YoY

+10.5%

EPS

$-0.21

EPS estimate

$-0.35

EPS came in at -0.21 against a street estimate of -0.35 — a beat of 40.0%.

Key statistics

Market cap

$269.8M

Forward P/E

0.0

P/B

1.29

Book value

$3.19

EPS (TTM)

$-1.06

52-week high

$10.08

52-week low

$2.90

50-day MA

$4.67

200-day MA

$5.43

Beta

0.37

Analyst view

Analysts rate Immuneering Corp a buy (4 buy, 1 hold, 0 sell out of 5) with an average price target of $18.86.

Shareholding

Insiders

13.82%

Institutions

48.49%

Largest institutional holders

Fund	Stake
FMR Inc	14.99%
Sanofi	4.19%
Vanguard Group Inc	3.97%
Vanguard Capital Management, LLC	3.54%
Marshall Wace Asset Management Ltd	3.09%
T. Rowe Price Associates, Inc.	2.83%
BlackRock Inc	2.33%
Millennium Management LLC	1.70%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Immuneering Corp — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.